On February 5, 2026, Cytokinetics (CYTK) disclosed two insider trading transactions. Executive Callos Andrew purchased 15,000 shares.
【Recent Insider Transactions】
Disclosure Date
Position
Name
Transaction Date
Buy/Sell
Quantity
Price per Share (USD)
Total Amount (USD)
February 5, 2026
Executive
Callos Andrew
February 5, 2026
Buy
15,000
23.26
348,900
February 5, 2026
Executive
Callos Andrew
February 5, 2026
Sell
15,000
61.93
929,000
February 2, 2026
Executive
Callos Andrew
February 2, 2026
Sell
886
62.10
55,000
February 2, 2026
Executive
Callos Andrew
February 2, 2026
Buy
886
37.63
33,300
January 20, 2026
Director
Daly James M
January 15, 2026
Buy
197
63.44
12,500
January 16, 2026
Director
Harrington Robert Arthur, HENDERSON JOHN T, Kaye Edward M. MD, WIERENGA WENDELL, Wysenski Nancy
January 15, 2026
Buy
924
63.44
58,600
January 5, 2026
Executive
Callos Andrew
January 5, 2026
Sell
15,000
60.28
904,200
January 5, 2026
Executive
Callos Andrew
January 5, 2026
Buy
15,000
23.26
348,900
January 2, 2026
Executive
Callos Andrew
January 2, 2026
Sell
885
63.16
55,900
January 2, 2026
Executive
Callos Andrew
January 2, 2026
Sell
913
62.09
56,700
【Company Profile】
Cytokinetics, Incorporated was founded on August 5, 1997, and is incorporated under Delaware law. It is a clinical-stage biopharmaceutical company primarily focused on discovering and developing novel small molecule therapies that modulate muscle function, aiming to provide potential treatments for serious diseases and medical conditions. The company is currently in the development phase, emphasizing research, drug screening technologies, and financing.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
US Stock Insider Trading | Cytokinetics disclosed two insider trading transactions on February 5
On February 5, 2026, Cytokinetics (CYTK) disclosed two insider trading transactions. Executive Callos Andrew purchased 15,000 shares.
【Recent Insider Transactions】
【Company Profile】
Cytokinetics, Incorporated was founded on August 5, 1997, and is incorporated under Delaware law. It is a clinical-stage biopharmaceutical company primarily focused on discovering and developing novel small molecule therapies that modulate muscle function, aiming to provide potential treatments for serious diseases and medical conditions. The company is currently in the development phase, emphasizing research, drug screening technologies, and financing.